The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer

Journal of Surgical Oncology

Volumn 109, Issue 7, 2014, Pages 665-675

  Demir, Lutfiye ^a,b   Ekinci, Nese ^a   Erten, Cigdem ^a   Somali, Isil ^b   Can, Alper ^a   Dirican, Ahmet ^a   Cokmert, Suna ^a   Bayoglu, Vedat ^a   Akyol, Murat ^a   Kucukzeybek, Yuksel ^a   Alacacioglu, Ahmet ^a   Tarhan, Mustafa Oktay ^a,b  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

cell proliferation markers; colon cancer; p53 mutation; prognosis

Indexed keywords

CELL CYCLE PROTEIN; CELL MARKER; CYCLIN A; CYCLIN D1; KI 67 ANTIGEN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; COLON CANCER; DISEASE FREE SURVIVAL; EXTRACAPSULAR NODAL INVASION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; VERY ELDERLY;

CELL PROLIFERATION MARKERS; COLON CANCER; P53 MUTATION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLIN A; CYCLIN D1; FEMALE; GENES, P53; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84899548667     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23563     Document Type: Article

References (46)

1. Siegel R, Naishadham D, Jemal A,: Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11.
2. Bilchik AJ, DiNome M, Saha S, et al.: Prospective multicenter trial of staging adequacy in colon cancer: Preliminary results. Arch Surg 2006; 141: 527-533.
3. Manfredi S, Bouvier AM, Lepage C, et al.: Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006; 93: 1115-1122.
4. O'Connell JB, Maggard MA, Ko CY,: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420.
5. Galizia G, Gemei M, Del Vecchio L, et al.: Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg 2012; 147: 18-24.
6. Falcone A, Ricci S, Brunetti I, et al.: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
7. Wolpin BM, Meyerhardt JA, Mamon HJ, et al.: Adjuvant treatment of colorectal cancer. CA Cancer J Clin 2007; 57: 168-185.
8. Langan RC, Mullinax JE, Raiji MT, et al.: Colorectal cancer biomarkers and the potential role of cancer stem cells. J Cancer 2013; 4: 241-250.
9. Sherr CJ, Roberts JM,: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
10. Alao J,: The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007; 6: 24.
11. Handa K, Yamakawa M, Takeda H, et al.: Expression of the cell cycle markers in colorectal carcinoma: Superiority of cyclin A as an indicator of poor prognosis. Int J Cancer 1999; 84: 225-233.
12. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-1715.
13. Lane DP,: Cancer: p53, guardian of the genome. Nature 1992; 358: 15-16.
14. Balint EE, Vousden KH,: Activation and activities of the p53 tumour supressor protein. Br J Cancer 2001; 85: 1813-1823.
15. Hari DM, Bilchik AJ,: Clinical decision-making and implementation challenges with the AJCC VII staging system for colorectal carcinoma. J Surg Oncol 2011; 105: 221-222.
16. Compton CC, Fielding LP, Burgart LJ, et al.: Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
17. Arber N, Hibshoosh H, Moss SF, et al.: Increased expression of cyclin D1 is an early event in multistage colorectal carcinogenesis. Gastroenterology 1996; 110: 669-674.
18. Palmqvist R, Stenling R, Oberg A, et al.: Expression of cyclin D1 and retinoblastoma protein in colorectal cancer. Eur J Cancer 1998; 34: 1575-1581.
19. Maeda K, Chung YS, Kang SM, et al.: Overexpression of cyclin D1 and p53 associated with disease recurrence in colorectal adenocarcinoma. Int J Cancer 1997; 74: 310-315.
20. McKay JA, Douglas JJ, Ross VG, et al.: Cyclin D1 protein expression in gene polymorphism in colorectal cancer. Int J Cancer 2000; 88: 77-81.
21. McKay JA, Douglas JJ, Ross VG, et al.: Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 2000; 6: 1113-1118.
22. McKay JA, Douglas JJ, Ross VG, et al.: Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol 2002; 196: 386-393.
23. Belt EJ, Brosens RP, Delis-van Diemen PM, et al.: Cell cycle proteins predict recurrence in stage II and III colon cancer. Ann Surg Oncol 2012; 19: S682-S692.
24. Bukholm IK, Nesland JM,: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 2000; 436: 224-228.
25. Lyall MS, Dundas SR, Curran S, et al.: Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 2006; 12: 1184-1191.
26. Bahnassy AA, Zekri AR, El-Houssini S, et al.: Cyclin A and Cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol 2004; 4: 22.
27. Holland TA, Elder J, McCloud JM, et al.: Subcellular localization of cyclin D1 protein in colorectal tumours is associated with p21(WAF1/CIP1) expression and correlates with patients survival. Int J Cancer 2001; 95: 302-336.
28. Ogino S, Nosho K, Irahara N, et al.: A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 2009; 15: 4431-4438.
29. Nosho K, Kawasaki T, Chan AT, et al.: Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. Histopathology 2008; 53: 588-598.
30. Hollstein M, Sidransky D, Vogelstein B, et al.: p53 mutations in human cancers. Science 1991; 253: 49-53.
31. Baas IO, Mulder JW, Offerhaus GJ, et al.: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
32. Munro AJ, Lain S, Lane DP,: P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005; 92: 434-444.
33. Bondi J, Husdal A, Bukholm G, et al.: Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J Clin Pathol 2005; 58: 509-514.
34. Habermann J, Lenander C, Roblick UJ, et al.: Ulcerative colitis and colorectal carcinoma: DNA profile, laminin-5 gamma 2 chain and cyclin A expression as early markers for risk assessment. Scand J Gastroenterol 2001; 36: 751-758.
35. Kubota Y, Petras RE, Easley KA, et al.: Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992; 70: 2602-2609.
36. Sahin AA, Ro JY, Brown RW, et al.: Assessment of Ki-67-derived tumor proliferative activity in colorectal adenocarcinomas. Mod Pathol 1994; 7: 17-22.
37. Suzuki H, Matsumoto K, Terabe M,: Ki-67 antibody labeling index in colorectal carcinoma. J Clin Gastroenterol 1992; 15: 317-320.
38. Compton CC,: Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol 2003; 16: 376-388.
39. Betge J, Pollheimer MJ, Lindtner RA, et al.: Intramural and extramural vascular invasion in colorectal cancer: Prognostic significance and quality of pathology reporting. Cancer 2012; 118: 628.
40. Wiggers T, Arends JW, Volovics A,: Regression analysis of prognostic factors in colorectal cancer after curative resections. Dis Colon Rectum 1988; 31: 33.
41. Chapuis PH, Dent OF, Fisher R, et al.: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985; 72: 698.
42. van der Gaag NA, ten Kate FJ, Lagarde SM, et al.: Prognostic significance of extra-capsular lymph node involvement in patients with adenocarcinoma of the ampulla of Vater. Br J Surg 2008; 95: 735-743.
43. Fleischmann A, Thalmann GN, Markwalder R, et al.: Prognostic implications of extracapsular extension of pelvic lymph node metastases in urothelial carcinoma of the bladder. Am J Surg Pathol 2005; 29: 89-95.
44. Griebling TL, Ozkutlu D, See WA, et al.: Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol 1997; 10: 804-809.
45. Al Sahaf O, Myers E, Jawad M, et al.: The prognostic significance of extramural deposits and extracapsular lymph node invasion in colon cancer. Dis Colon Rectum 2011; 54: 982-988.
46. Komori K, Kanemitsu Y, Kimura K, et al.: Detailed stratification of TNM stage III rectal cancer based on the presence/absence of extracapsular invasion of the metastatic lymph nodes. Dis Colon Rectum 2013; 56: 726-732.